NCI is using a stepwise approach to assess the potential of various agents to inhibit, reverse and/or delay the carcinogenic process in various organs. One of the preclinical evaluations of potential chemopreventive agents is the demonstration of agent efficacy in preventing cancer in laboratory animal models. Both carcinogen-induced and transgenic animals are used for this purpose. Another area of preclinical development in chemopreventive agents is the development of surrogate intermediate endpoint biomarkers. Such biomarkers must be translatable to the clinic trial situation in order to shorten the time required to evaluate agents clinically in Phase II trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN43308-6-0-1
Application #
7693497
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2008
Total Cost
$1,406,468
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130